ストックスクリーナーアプリを入手
4.22
1.63%
-0.07
アフターアワーズ：
4.28
0.06
+1.42%
前日終値:
$4.29
開ける：
$4.26
24時間の取引高:
840.93K
Relative Volume:
1.18
時価総額：
$418.40M
収益：
$9.01M
当期純損益:
$-99.72M
株価収益率:
-0.9299
EPS:
-4.5381
ネットキャッシュフロー:
$-92.85M
1週間 パフォーマンス:
-9.05%
1か月 パフォーマンス:
+4.98%
6か月 パフォーマンス:
+23.75%
1年 パフォーマンス:
+34.39%
1日の値動き範囲:
$4.05
$4.33
1週間の範囲:
$4.05
$4.6328
52週間の値動き範囲:
$2.45
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.22 | 425.34M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan
Layoff Tracker: MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles - BioSpace
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance
XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - MarketBeat
Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q2 Earnings Snapshot - Yahoo Finance
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals (NASDAQ: XFOR) wins EU nod, posts $16.2M Q2 loss - Stock Titan
XFOR Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Perceptive Advisors LLC Increases Stake in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Form 4 Supernus Pharmaceuticals Inc For: 31 July By Investing.com - Investing.com UK
XFOR|X4 Pharmaceuticals Inc|Price:3.980|Chg%:-0.020 - TradingKey
BlackRock (NYSE: BLK) discloses 5.9% ownership of X4 Pharmaceuticals (XFOR) stock - Stock Titan
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com UK
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Cash Flow - TradingKey
XFOR|X4 Pharmaceuticals Inc|Price:3.930|Chg%:+0.080 - TradingKey
X4 Pharmaceuticals Inc (XFOR) Balance Sheet - TradingKey
X4 Pharmaceuticals Market Sentiment - Benzinga España
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – FWB:48Q0 - TradingView
XFOR|X4 Pharmaceuticals Inc|Price:3.850|Chg%:-0.140 - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:XFOR - TradingView
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News
Frontier tech research, news & data - MLQ.ai
Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Canada
Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout - Stock Titan
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman |
Aug 12 '26 |
Sale |
4.44 |
47,436 |
210,829 |
328,651 |
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):